Introduction {#Sec1}
============

Dipeptidyl peptidase (DPP)-4 inhibitors are oral antidiabetic agents that act by inhibiting the degradation of the gastrointestinal incretin hormones, glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP), by the DPP-4 enzyme \[[@CR1], [@CR2]\]. The resulting increase in availability of these hormones stimulates glucose-dependent insulin release from pancreatic beta cells, while reducing glucagon output from pancreatic alpha cells \[[@CR3]\].

Although there is no consensus on the best choice of antihyperglycemic agent for patients in whom metformin fails to maintain glycemic control, it has been suggested that the addition of a DPP-4 inhibitor may be appropriate, as these compounds seem to have a similar effect on glycated hemoglobin (HbA~1c~) compared with sulfonylureas or thiazolidinediones, but without the risk of hypoglycemia or weight gain \[[@CR4]\].

Linagliptin is a xanthine-based DPP-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). Like most DPP-4 inhibitors, the pharmacological features of linagliptin permit once daily dosing, without the need for dose titration \[[@CR5], [@CR6]\]. However, unlike other DPP-4 inhibitors, the excretion of linagliptin is largely via the bile and gut and, therefore, dose adjustment is not required in patients with declining renal function \[[@CR7], [@CR8]\].

Several clinical trials have demonstrated that linagliptin elicits reductions in HbA~1c~, fasting plasma glucose (FPG), and postprandial glucose (PPG) in patients with T2DM \[[@CR6], [@CR9]--[@CR13]\].

The aim of the present study was to explore further the mechanisms underlying the improvements in glycemic control observed with linagliptin.

Materials and Methods {#Sec2}
=====================

Study Population {#Sec3}
----------------

Patients aged between 18 and 80 years, with a body mass index of 40 kg/m^2^ or less at screening, who were either treatment naive or had previously received monotherapy with oral antidiabetic agents and whose HbA~1c~ level was between 6.5% (≥47.4 mmol/mol) and 10.0% (≤85.8 mmol/mol) were eligible.

The main exclusion criteria included myocardial infarction, stroke, or transient ischemic attack within 6 months before enrollment; impaired hepatic function; renal insufficiency; hypersensitivity or allergy to linagliptin, sitagliptin, or excipients; or treatment with rosiglitazone, pioglitazone, GLP-1 analogs, insulin, DPP-4 inhibitors, or anti-obesity drugs during the previous 3 months.

An independent ethics committee (Ärztekammer Nordrhein, Düsseldorf, Germany) approved the study, which was conducted according to the Declaration of Helsinki and the International Conference on Harmonisation harmonised tripartite guideline for good clinical practice. All patients gave written, informed consent to participate.

Study Design {#Sec4}
------------

This phase 2a, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study compared oral linagliptin (5 mg once daily) with placebo. While a sitagliptin arm (100 mg orally once daily) was included as a "positive control", the study was not statistically powered to compare the linagliptin and sitagliptin arms.

Patients already taking one oral antidiabetic medication underwent a 2-week washout. All patients underwent a 2-week, open-label, placebo run-in, followed by a 4-week treatment period with linagliptin, sitagliptin, or placebo. Post-treatment follow-up lasted 2 weeks.

Patients were randomly assigned using an interactive voice response system, stratified by HbA~1c~ at the beginning of the placebo run-in \[\<8.5% vs. ≥8.5% (\<69.4 vs. ≥69.4 mmol/mol)\] and previous use of antidiabetic drugs.

Sitagliptin was over-encapsulated to maintain blinding of treatment allocation.

Study Assessments {#Sec5}
-----------------

Baseline measurements were made on day −1 (the day before randomization), and the study assessments \[including meal tolerance test (MTT)\] were performed on days 1, 28, 29, and 30. Repeated blood samples were taken to obtain blood glucose and hormone measurements, as described in detail later. Longer-term markers of blood glucose control were evaluated on days −1, 15, 28, and 42.

The MTT consisted of two nutrition bars (which, together, provided 300 kCal, and contained 13 g protein, 40 g carbohydrate, and 10 g fat) and a high energy, high protein drink (which provided 300 kCal, and contained 16 g protein, 90 g carbohydrate, and 6 g fat). Markers determined after each MTT included plasma glucose, intact GLP-1, intact GIP, glucagon, insulin, and C-peptide levels. Longer-term markers of glycemic control included HbA~1c~, fructosamine, and 1,5-anhydroglucitol.

Plasma glucose was measured electrochemically with a biosensor-based assay (Super GL, Hitado, Möhnesee-Delecke, Germany). Intact GLP-1 was measured by a fluorescence-based enzyme-linked immunosorbent assay, using a Linco research system (Linco Research Inc., St Charles, MO, USA) instrument. Plasma DPP-4 levels were determined using a semiquantitative enzyme activity assay with fluorescence detection, which has been described previously \[[@CR14]\].

Levels of intact GIP and HbA~1c~ were measured as described previously \[[@CR15]--[@CR17]\]. International Federation of Clinical Chemistry values for HbA~1c~ were converted from percentages to mmol/mol. Glucagon, insulin, and C-peptide levels were analyzed using specific immunoassays. Levels of fructosamine and 1,5-anhydroglucitol were measured using specific enzymatic assays.

Throughout the study, safety was assessed based on adverse event frequencies and severities, vital signs, 12-lead electrocardiogram, physical examination, and laboratory tests.

Endpoints {#Sec6}
---------

The primary assessments, after 28 days of treatment, were change from baseline in weighted mean glucose (WMG), and change from baseline in the area under the time--effect curve between 0 and 2 h (AUEC~0−2h~) for GLP-1 following a MTT. The secondary assessments were change in FPG from baseline to day 28, and change in plasma glucose (AUEC~0−3h~) following a MTT from baseline to day 28.

Additional pharmacodynamic assessments included levels of intact GIP, glucagon, insulin, C-peptide, 2-h PPG, and inhibition of plasma DPP-4.

Areas under the curves were determined with the trapezoidal rule. For WMG, the area under the glucose concentration--time curve over 24 h was divided by 24.

Statistical Analyses {#Sec7}
--------------------

The primary, secondary, and other quantitative pharmacodynamic endpoints were evaluated using an analysis of covariance model with treatment as the fixed effect. For each endpoint, the corresponding baseline value (obtained at day −1) was included in the model as a linear covariate. The variables, previous use of antidiabetic agents, and HbA~1c~ \[\<8.5% vs. ≥8.5% (\<69.4 vs. ≥69.4 mmol/mol)\] at baseline, were included in the model, as the randomization was stratified using these parameters. Testing of superiority of linagliptin versus placebo for the primary and secondary endpoints after 4 weeks of treatment was performed (one-sided at the 0.025 level). The Wilcoxon--Mann--Whitney test was used for treatment comparisons of DPP-4 inhibition, and Hodges--Lehmann estimates for the median differences and their confidence intervals (CIs).

For sample size estimation, the placebo-adjusted change from baseline in WMG was assumed to be −17.2 mg/dL (0.95 mmol/L), with a SD of 22.6 mg/dL (1.25 mmol/L) (based on a study by Brazg et al. \[[@CR18]\]). Lower variability was assumed for the other primary endpoint, GLP-1 AUEC~0--2h~. Based on these assumptions, 38 completers per treatment arm were needed to achieve a power of 90% for the change in WMG, whereas the power was greater than 98% for GLP-1 AUEC~0--2h~.

A per protocol set of patients was created for analyses of the primary and secondary endpoints to compare linagliptin with placebo. In addition, an exploratory analysis was performed using the data obtained from subjects receiving sitagliptin treatment. However, the trial was not designed or sufficiently powered to compare the efficacy or tolerability of linagliptin with sitagliptin.

Results {#Sec8}
=======

Demographic and Baseline Characteristics {#Sec9}
----------------------------------------

Demographic and baseline characteristics were similar across the patient groups. The mean (SD) baseline values for HbA~1c~ were 7.3% (0.53%), and for FPG were 9.25 (1.53) mmol/L. Diabetes medications used previously (67.8% of patients) were metformin (55.4%), sulfonylureas (9.1%), and glinides (3.3%). A total of 121 patients was randomly assigned (40 to placebo, 40 to linagliptin, and 41 to sitagliptin). Three patients (2.5%) withdrew from the study prematurely: two patients in the placebo arm who experienced hyperglycemia, and one patient in the linagliptin group for whom there was difficulty in obtaining blood samples. One subject in the placebo group had a protocol violation that was considered to be important during blinded review (incorrect timing of administration of trial medication). The analysis of secondary, but not the primary, endpoints excluded this patient and was performed using data obtained from the 117 patients who completed the study without relevant protocol violations. Data on demographics, baseline characteristics, and safety were derived from the complete patient set (*n* = 121).

Primary and Secondary Endpoints {#Sec10}
-------------------------------

After 4 weeks of treatment, linagliptin elicited decreases in 24-h WMG and increases in GLP-1 AUEC~0--2h~ (Table [1](#Tab1){ref-type="table"}). These changes were significantly larger than those seen with placebo (*P* \< 0.0001 for all comparisons). Likewise, linagliptin achieved significant placebo-corrected changes from baseline for FPG and for glucose AUEC~0--3h~.Table 1Primary (changes in WMG and GLP-1 AUEC~0--2h~) and secondary (changes in FPG and glucose AUEC~0--3h~) endpoints after 28 days of treatment with linagliptin (5 mg once daily) or placeboPlaceboLinagliptinPrimary endpoints 24h-WMG (mmol/L)  Baseline mean (SE)10.6 (0.3)10.5 (0.4)  Adjusted mean change from baseline (SE)0.01 (0.2)−1.1 (0.2)  Comparison vs. placebo: adjusted mean change (95% CI)--−1.1 (−1.6, −0.7)  *P-*value--\<0.0001 Intact GLP-1 AUEC~0--2h~ (pmol/h/L)  Baseline mean (SE)15.0 (1.9)17.4 (1.8)  Adjusted mean change from baseline (SE)0.4 (2.1)18.5 (2.1)  Comparison vs. placebo: adjusted mean change (95% CI)--18.1 (12.4, 23.9)  *P-*value--\<0.0001Secondary endpoints FPG mmol/h/L  Baseline mean (SE)9.4 (0.2)9.2 (0.2)  Adjusted mean change from baseline (SE)−0.01 (0.2)−0.6 (0.2)  Comparison vs. placebo: adjusted mean change (95% CI)--−0.6 (−1.1, −0.1)  *P-*value--0.0283 Glucose AUEC~0--3h~ (mmol/h/L)  Baseline mean (SE)40.1 (1.2)40.4 (1.3)  Adjusted mean change from baseline (SE)0.4 (0.8)−5.5 (0.8)  Comparison vs. placebo: adjusted mean change (95% CI)--−5.9 (−8.2, −3.7)  *P-*value--\<0.0001*AUEC* area under the time--effect curve, *CI* confidence interval, *FPG* fasting plasma glucose, *GLP-1* glucagon-like peptide-1, *SE* standard error, *WMG* weighted mean glucose

Inhibition of DPP-4 {#Sec11}
-------------------

Median DPP-4 inhibition achieved by linagliptin treatment at trough was 79.8% at day 2 (24 h after the first dose). DPP-4 inhibition by linagliptin was then sustained at 80% or greater throughout the treatment period. On day 28, median DPP-4 inhibition at trough was 82.2% for linagliptin and 70.3% for sitagliptin (estimate of median difference: 12.6%; 95% CI 9.5% to 15.7%; *P* \< 0.0001). Two weeks after the last dose of linagliptin to plasma DPP-4 was still inhibited by approximately 17%.

Effects on Incretins and Other Peptide Hormones {#Sec12}
-----------------------------------------------

Linagliptin therapy increased placebo-corrected intact GIP AUEC~0--2h~ by approximately 1.5-fold on day 1 (from a baseline value of 129.9 ± 9.0 pmol/h) with approximately a two-fold increase observed on day 28 (Table [2](#Tab2){ref-type="table"}). Data for intact GLP-1 AUEC~0--2h~ on day 1 were in line with these data, showing increases of similar magnitude on days 1 and 28 (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Placebo-corrected levels of glucagon decreased significantly on days 1 and 28 with linagliptin. For insulin and C-peptide, changes from baseline were not significant.Table 2Exploratory endpoints: baseline values (day --1) and adjusted mean changes from baseline on days 1, 15, and 28 (where data available)**Day 1Day 15Day 28PlaceboLinagliptinPlaceboLinagliptinPlaceboLinagliptin**Intact GLP-1 AUEC~0--2h~ (pmol/h/L) Baseline (SE)14.6 (1.9)17.4 (1.8)----See Table [1](#Tab1){ref-type="table"} Mean change from baseline0.811.3---- Comparison vs. placebo (95% CI)--10.5 (6.5, 14.6)---- *P-*value--\<0.0001----Intact GIP AUEC~0--2h~ (pmol/h/L) Baseline (SE)105.2 (7.2)129.9 (9.0)----105.2 (7.2)129.9 (9.0) Mean change from baseline28.769.5----15.2106.6 Comparison vs. placebo (95% CI)--40.7 (13.9, 67.5)------91.4 (67.0, 115.8) *P-*value--0.003------\<0.0001Total GIP AUEC~0--2h~ (pmol/h/L) Baseline (SE)239.6 (18.1)301.4 (21.2)----239.6 (18.1)301.4 (21.2) Mean change from baseline50.5−82.8----12.6−94.0 Comparison vs. placebo (95% CI)--−133.3 (−186.6, −80.0)------−106.7 (−147.9, −65.4) *P*-value--\<0.0001------\<0.0001Insulin AUEC~0--2h~ (mU/h/L) Baseline (SE)87.6 (6.9)100.6 (8.5)----87.6 (6.9)102.4 (8.2) Mean change from baseline19.715.5----7.2−0.7 Comparison vs. placebo (95% CI)--−4.3 (−19.1, 10.6)------−8.0 (−22.3, 6.4) *P-*value--0.57------0.27C-peptide AUEC~0--2h~ (pmol/h/L) Baseline (SE)4,515.0 (212.7)5,081.0 (232.4)----4,515.0 (212.7)5,161.4 (238.5) Mean change from baseline716.7394.4----−121.6−146.5 Comparison vs. placebo (95% CI)--−322.3 (−684.7, 40.1)------−24.8 (−445.7, 396.0) *P-*value--0.08------0.91Glucagon AUEC~0--2h~ (pg/h/mL) Baseline (SE)183.0 (11.5)182.1 (6.6)----183.0 (11.5)182.1 (6.6) Mean change from baseline17.3−6.1----1.3−17.4 Comparison vs. placebo (95% CI)--−23.4 (−36.8, −10.1)------−18.7 (−37.0, −0.4) *P-*value--0.0008------0.04522-h PPG (mmol/L) Baseline (SE)14.6 (0.6)14.8 (0.6)----14.6 (0.6)14.8 (0.6) Mean change from baseline−0.2−1.3----0.1−2.3 Comparison vs. placebo (95% CI)--−1.1 (−1.9, −0.3)------−2.4 (−3.5, −1.3) *P-*value--0.009------\<0.0001Peak glucose (mmol/L) Baseline (SE)15.8 (0.5)15.9 (0.5)----15.8 (0.5)15.9 (0.5) Mean change from baseline0.2−1.5----0.04−2.2 Comparison vs. placebo (95% CI)--−1.7 (−2.4, 1.0)------−2.2 (−3.2, 1.3) *P-*value--\<0.0001------\<0.0001FPG\* (mmol/L) Baseline (SE)9.5 (0.2)9.2 (0.2)9.5 (0.2)9.2 (0.2)See Table [1](#Tab1){ref-type="table"} Mean change from baseline0.090.030.2−0.5 Comparison vs. placebo (95% CI)--−0.1 (−0.6, 0.4)--−0.6 (−1.1, −0.2) *P-*value--0.7952--0.01Glucose AUEC~0--3h~ (mmol/h/L) Baseline (SE)40.2 (1.3)40.4 (1.4)----See Table [1](#Tab1){ref-type="table"} Mean change from baseline0.3−3.0---- Comparison vs. placebo (95% CI)--−3.3 (−4.8, −1.7)---- *P-*value--0.0001----24-h WMG (mmol/L) Baseline (SE)10.6 (0.3)10.5 (0.4)----See Table [1](#Tab1){ref-type="table"} Mean change from baseline0.04−0.5---- Comparison vs. placebo (95% CI)--−0.5 (−0.7, −0.3)---- *P-*value--\<0.0001----HbA~1c~ (%) Baseline (SE)----7.42 (0.1)7.31 (0.1)7.42 (0.1)7.31 (0.1) Mean change from baseline----−0.10−0.15−0.06−0.27 Comparison vs. placebo (95% CI)------−0.05 (−0.14, 0.05)--−0.22 (−0.35, −0.08) *P-*value------0.31--0.002HbA~1c~, mmol/mol, IFCC Baseline (SE)----57.6 (1.1)56.4 (1.1)57.6 (1.1)56.4 (1.1) Mean change from baseline----−1.1−1.6−0.7−3.0 Comparison vs. placebo (95% CI)------−0.5 (−1.5, 0.5)--−2.4 (−3.8, −0.9) *P-*value------0.31--0.002Fructosamine (μmol/L) Baseline (SE)----257.2 (6.4)255.1 (5.4)257.6 (6.2)257.6 (6.1) Mean change from baseline----17.09.02.9−6.1 Comparison vs. placebo (95% CI)------−7.9 (−17.6, 1.8)--−9.0 (−17.9, −0.2) *P-*value------0.1069--0.04461,5-Anhydroglucitol (μg/mL) Baseline (SE)----9.3 (1.0)10.2 (1.1)9.3 (1.0)9.9 (1.0) Mean change from baseline----−0.50.8−0.81.0 Comparison vs. placebo (95% CI)------1.3 (0.8, 1.8)--1.8 (1.0, 2.5) *P-*value------\<0.0001--\<0.0001Data shown are adjusted mean change from baseline\* FPG measured on day 2*--* no data available*AUEC* area under the time--effect curve, *CI* confidence interval, *FPG* fasting plasma glucose, *GIP* glucose-dependent insulinotropic polypeptide, *GLP-1* glucagon-like peptide-1, *HbA*~*1c*~ glycated hemoglobin, *IFCC* international federation of clinical chemistry, *PPG* postprandial glucose, *SE* standard error, *WMG* weighted mean glucose

Following a MTT on day 28, mean plasma concentrations of intact GLP-1 increased in the linagliptin-treated group compared with placebo, at all time points evaluated (Fig. [1](#Fig1){ref-type="fig"}). In line with these changes, mean plasma glucagon levels were reduced in the linagliptin-treated group versus placebo.Fig. 124-h profile of mean plasma glucose (**a**), changes in intact GLP-1 (**b**), intact GIP (**c**), and glucagon over 2.5 h following a meal tolerance test (**d**), for subjects allocated to the linagliptin or placebo arms (day 28). Data are shown as mean ± standard error. Time point 0, shown at the start of the weighted mean glucose interval, corresponds to approximately 8:00 a.m. *GIP* glucose-dependent insulinotropic polypeptide, *GLP* glucagon-like peptide

Effects on Plasma Glucose Parameters {#Sec13}
------------------------------------

The placebo-adjusted changes from baseline of plasma glucose parameters following linagliptin therapy were statistically significant on days 1 and 28, including 2-h PPG, peak glucose, glucose AUEC~0--3h~, and 24-h WMG (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). For FPG, the placebo-adjusted change from baseline was not significant on day 1 but reached statistical significance on day 28.

Placebo-adjusted means for HbA~1c~ showed a nonsignificant reduction on day 15 and significant reductions on days 28 (Table [2](#Tab2){ref-type="table"}) and 42 (−0.28%; 95% CI −0.42 to −0.13; *P* = 0.0003). Fructosamine showed a significant reduction from baseline on day 28, but not on day 15 of treatment (Table [2](#Tab2){ref-type="table"}) or at 2 weeks post-treatment (day 42) (−5.1 μmol/L; 95% CI −16.8 to 6.5; *P* = 0.3848). There were significant increases from baseline in 1,5-anhydroglucitol levels on days 15 and 28 (Table [2](#Tab2){ref-type="table"}), but at 2 weeks post-treatment (day 42) the increase was not statistically significant (0.8 μg/mL; 95% CI −1.0 to 2.6; *P* = 0.3634).

The 24-h glucose profile, evaluated on day 28, showed that linagliptin was associated with lower mean plasma glucose concentrations at all time points, compared with placebo (Fig. [1](#Fig1){ref-type="fig"}).

Results obtained on days 29/30 were essentially similar; therefore, only data from day 28 are presented.

Exploratory Analyses: Linagliptin versus Sitagliptin {#Sec14}
----------------------------------------------------

Additional exploratory sensitivity analyses, including all three study treatments, compared the effects of linagliptin (*n* = 39) and sitagliptin (*n* = 40) on the primary and secondary endpoints, between baseline and day 28. The reduction of WMG was numerically greater with sitagliptin compared with linagliptin on day 28 (difference of 0.3 ± 0.2 mmol/L; 95% CI −0.1 to 0.8; *P* = 0.1274). The corresponding increase in intact GLP-1 AUEC~0--2h~ was numerically greater with linagliptin than with sitagliptin (difference of 2.8 ± 2.7 pmol/h/L; 95% CI −2.7 to 8.2; *P* = 0.3130). For FPG and glucose AUEC~0--3h~, the reductions were numerically greater for sitagliptin versus linagliptin, with differences of 0.3 ± 0.2 mmol/L (95% CI −0.2 to 0.8; *P* = 0.2281) and 1.3 ± 1.0 mmol/h/L (95% CI −0.8 to 3.3; *P* = 0.2230), respectively. None of the observed differences between linagliptin and sitagliptin, for primary and secondary endpoints, were statistically significant.

Safety and Tolerability {#Sec15}
-----------------------

The safety analysis comprised 121 patients who had received at least one dose of trial medication. Forty-three patients (35.5%) experienced at least one adverse event during the study (Table [3](#Tab3){ref-type="table"}). However, most adverse events were mild and there were no severe or serious adverse events; no adverse events led to treatment discontinuation. During the washout phase, one patient experienced two severe adverse events that were not considered to be treatment related (aggravated migraine and a panic attack that required hospitalization). Headache, back pain, and nasopharyngitis were the most frequently reported adverse events. Drug-related adverse events occurred in one patient (2.5%) in the placebo group (upper abdominal pain), two patients (5.0%) in the linagliptin-treated group (headache and hyperhydrosis), and five patients (12.2%) in the sitagliptin-treated group \[headache (two patients), hot flush, abdominal distension, rhinorrhea, and dry mouth\]. Hypoglycemia was not reported in any treatment group. No clinically relevant changes in vital signs were observed.Table 3Summary of adverse events that were reported in two or more patients of any treatment group (in order of frequency)*n* (%)PlaceboLinagliptinSitagliptinNumber of patients40 (100)40 (100)41 (100)Total with adverse events13 (32.5)12 (30.0)18 (43.9)Headache3 (7.5)4 (10.0)5 (12.2)Back pain2 (5.0)3 (7.5)1 (2.4)Nasopharyngitis1 (2.5)2 (5.0)2 (4.9)Epistaxis0 (0.0)2 (5.0)0 (0.0)Arthralgia0 (0.0)2 (5.0)0 (0.0)

Discussion {#Sec16}
==========

This study provides the most detailed comparison to date of the acute and longer-term effects of linagliptin on glycemic control in patients with insufficiently controlled T2DM. In this study, orally administered linagliptin, 5 mg once daily, significantly improved 24-h glycemic control compared with placebo, as indicated by a reduction in plasma WMG levels. Twenty-four hours after the first dose of linagliptin, median DPP-4 inhibition was approximately 80%, which has previously been proposed as the threshold for effective glycemic control \[[@CR19]\]. Inhibition of DPP-4 was sustained throughout the 4-week study, with a low level (17%) detectable even 2 weeks after the end of linagliptin administration. These findings are consistent with stable binding of linagliptin to DPP-4 and the long terminal half-life of the drug (128--184 h in healthy individuals) \[[@CR14]\].

In accordance with these findings, linagliptin improved HbA~1c~ levels and longer-term markers of glycemic control, i.e., fructosamine and 1,5-anhydroglucitol levels. The effect on HbA~1c~ was maintained 2 weeks after treatment cessation. As 1,5-anhydroglucitol competes with glucose for renal tubular reabsorption \[[@CR20]\], it gives a better reflection of postmeal glycemic excursions than HbA~1c~ or fructosamine \[[@CR21], [@CR22]\]. Indeed, in this study, linagliptin primarily reduced PPG levels rather than FPG; FPG was virtually unchanged 24 h after the first dose and moderately reduced (a decrease of approximately 6% vs. baseline) after 4 weeks. In contrast, after 4 weeks of linagliptin administration, the change from baseline in plasma glucose 2 h after MTT (PPG) was 2.4 mmol/L (a decrease of approximately 15%). As the patients in this study had reasonably good glycemic control (mean baseline HbA~1c~ was 7.30 ± 0.53%), this may be a result of the glucose-dependent blood glucose-lowering effect that has been observed with DPP-4 inhibitors in general \[[@CR3]\].

Medium-term markers of glycemic control might be more appropriate than HbA~1c~ to evaluate the potential of linagliptin to improve blood glucose control in a study with a 4-week treatment duration. Nevertheless, HbA~1c~ was included in the efficacy parameters following the recent findings of a significant effect of linagliptin on HbA~1c~ after 4 weeks of treatment \[[@CR9]\]. The results presented here seem to be in accordance with previous studies; Nonaka et al. \[[@CR23]\] reported a placebo-adjusted decrease in WMG of 1.4 mmol/L with sitagliptin 100 mg in Japanese patients with T2DM. In a mostly non-Asian population of patients with T2DM with a slightly higher baseline HbA~1c~ (7.7 ± 0.8%; 57 ± 0.7 mmol/mol), 4 weeks of treatment with sitagliptin, added to a preexisting metformin therapy, resulted in a placebo-adjusted decrease in WMG of approximately 1 mmol/L \[[@CR18]\]. HbA~1c~ was not reported in these studies in which sitagliptin was evaluated over a treatment period of 4 weeks; however, but the effect of sitagliptin on HbA~1c~ lowering in moderately controlled (HbA~1c~ \<8%; 64 mmol/mol) elderly patients over 12 weeks of treatment (0.5%) \[[@CR24]\] was not considerably greater than that observed with linagliptin over only 4 weeks in the present study (0.3%). Therefore, the observed effect of linagliptin on HbA~1c~ seems to be within the range expected in patients with fairly well-controlled T2DM.

Inhibition of DPP-4 by linagliptin, and the resulting increases in GLP-1 levels, were accompanied by changes in GIP and other peptide hormones. The increased presence of intact GLP-1 in plasma was also associated with significant reductions in glucagon (peak excursion and AUEC~0--2h~) from day 1 of linagliptin administration. Furthermore, linagliptin produced significant reductions of approximately 15% in peak glucagon (data not shown) and approximately 10% in AUEC~0--2h~, on both days 1 and 28.

It is well established that glucagon secretion exhibits characteristic abnormalities in T2DM. Frequently, patients have fasting hyperglucagonemia and exaggerated responses to meal tests \[[@CR25]\]. GLP-1 is an inhibitor of glucagon secretion and also retains this ability in patients with T2DM \[[@CR26]\]. It has recently been suggested that the clinical importance of the GLP-1-induced insulin stimulation and glucagon inhibition contribute equally to the glucose-lowering effect of GLP-1 in patients with T2DM \[[@CR27]\]. Therefore, it is fair to assume that both the significant increase in GLP-1 and the decrease in glucagon levels accounted for the glucose-lowering potential of linagliptin in this study.

Importantly, GLP-1 elevation by DPP-4 inhibitors does not impair the counterregulatory response of glucagon to hypoglycemia \[[@CR28]\]. Furthermore, linagliptin is associated with a negligible risk of hypoglycemia when administered as monotherapy. Indeed, no patient developed symptomatic hypoglycemia while receiving either of the DPP-4 inhibitors in this study, confirming the low risk observed in previous studies \[[@CR6], [@CR9], [@CR14], [@CR29]--[@CR31]\].

The absence of any significant effects of linagliptin administration on insulin and C-peptide peak excursion or AUEC~0--2h~ indicate that insulin levels are maintained despite a concomitant reduction in glucose levels. This suggests improved responsiveness of the pancreatic beta cells to glucose levels and an insulinotropic effect. It is important to note that GLP-1-mediated insulin secretion is glucose-dependent and, as linagliptin reduced both the peak excursion and AUEC~0--3h~ of glucose within 1 day, the interpretation of insulin and C-peptide data may need to take this into account. This presumably explains why no changes in insulin and C-peptide have been observed, and is in accordance with previous studies that did not find treatment-related changes in absolute fasting and postprandial insulin levels or in C-peptide levels \[[@CR18], [@CR32]\].

At present, there are no published head-to-head comparison studies between linagliptin and sitagliptin. Although this trial was not designed or sufficiently powered to compare the efficacy of these two drugs, exploratory analyses indicated no clinically or statistically significant differences in the efficacy of these two drugs, in terms of changes in 24-h WMG and intact GLP-1, or secondary endpoints, including FPG and glucose AUEC~0--3h~, after 28 days of treatment. This finding is consistent with the authors' observation of a similar extent of DPP-4 inhibition by both linagliptin and sitagliptin. It is also consistent with current understanding of the mode of action of these two drugs, which, as a result of DPP-4 inhibition, produce sustained increases in GLP-1 levels, resulting in a lowering of plasma glucose levels.

The safety findings in this study indicate that linagliptin 5 mg once daily was well tolerated, with an adverse event rate that was not higher than that observed with placebo. Overall, linagliptin and sitagliptin showed similar efficacy and tolerability.

Conclusion {#Sec17}
==========

In summary, the findings of this study show that linagliptin has a rapid onset of action in patients with T2DM, producing potent inhibition of DPP-4. This results in immediate and sustained increases in both intact GLP-1 and GIP. Most importantly, it results in statistically significant and clinically meaningful improvements in glycemic control that are similar to those previously reported for other DPP-4 inhibitors administered for a 4-week treatment period. Linagliptin treatment was well tolerated, did not cause hypoglycemia, and had an adverse event rate that was similar to both placebo and sitagliptin. Overall, linagliptin has shown similar efficacy and tolerability compared with other DPP-4 inhibitors. However, in contrast to other agents of its class, linagliptin is mainly eliminated unchanged via the bile and the gut, with little reliance on renal excretion; consequently, it does not require dose adjustment in patients with, or at risk of, declining renal function.
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